Assignee
INXMED NANJING CO LTD
CN·8 granted patents·9 pending applications·4 citations·filing 2019–2025
Top patents by PatentIndex Score
17 records- 0189US12115160B2Combined use of IN10018 and PLDINXMED NANJING CO LTD·Filed 2023·Granted Oct 15, 2024·1 cites·18 claims
- 0288US12097200B2Combination of BI853520 with chemotherapeutic drugsINXMED NANJING CO LTD·Filed 2023·Granted Sep 24, 2024·1 cites·17 claims
- 0388US12059421B2Use of BI853520 in cancer treatmentINXMED NANJING CO LTD·Filed 2023·Granted Aug 13, 2024·1 cites·15 claims
- 0484US11986477B2Drug combination and use for treating tumorsINXMED NANJING CO LTD·Filed 2023·Granted May 21, 2024·1 cites·15 claims
- 0577US11999719B2Solid form of compoundINXMED NANJING CO LTD·Filed 2023·Granted Jun 4, 2024·0 cites·12 claims
- 0676US12257251B2Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutationINXMED NANJING CO LTD·Filed 2023·Granted Mar 25, 2025·0 cites·15 claims
- 0764US12121519B2Use of BI853520 in cancer treatmentINXMED NANJING CO LTD·Filed 2020·Granted Oct 22, 2024·0 cites·4 claims
- 0863US2024307395A1Use of bi853520 in cancer treatmentINXMED NANJING CO LTD·Filed 2024·Application pending·0 cites
- 0962US2024285627A1Drug combination of fak inhibitor and immunogenic cell death inducer and use thereofINXMED NANJING CO LTD·Filed 2024·Application pending·0 cites
- 1062US2024261285A1Combination of bi853520 with chemotherapeutic drugsINXMED NANJING CO LTD·Filed 2024·Application pending·0 cites
- 1161US2023278985A1Solid form of compoundINXMED NANJING CO LTD·Filed 2021·Application pending·0 cites
- 1258US2023145356A1Use of fak inhibitor in preparation of drug for treating tumors having nras mutationINXMED NANJING CO LTD·Filed 2020·Application pending·0 cites
- 1357US11440916B2Selective A2A receptor antagonistINXMED NANJING CO LTD·Filed 2019·Granted Sep 13, 2022·0 cites·14 claims
- 1457US2025049828A1Pharmaceutical composition for treating tumors and useINXMED NANJING CO LTD·Filed 2022·Application pending·0 cites
- 1557US2026048053A1Use of bi853520 in cancer treatmentINXMED NANJING CO LTD·Filed 2025·Application pending·0 cites
- 1657US2025099450A1Pharmaceutical combination for treating tumors and use thereofINXMED NANJING CO LTD·Filed 2023·Application pending·0 cites
- 1757US2023079055A1Combination of bi853520 with chemotherapeutic drugsINXMED NANJING CO LTD·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when INXMED NANJING CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →